Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347952 | 1.00 | TAS1R3 (0.38) | TAS1R3TAS1R1CNR2CNR1ATM | |
| SCHEMBL16373137 | 0.96 | PTGS1 (0.38) | TAS1R3TAS1R1CNR2CNR1ATM | |
| SCHEMBL19755664 | 0.96 | PTGS1 (0.38) | TAS1R3TAS1R1CNR2CNR1ATM | |
| SCHEMBL13380101 | 0.96 | PTGS1 (0.38) | TAS1R3TAS1R1CNR2CNR1ATM | |
| SCHEMBL19755665 | 0.96 | PTGS1 (0.38) | TAS1R3TAS1R1CNR2CNR1ATM | |
| SCHEMBL21100961 | 0.96 | PTGS1 (0.38) | TAS1R3TAS1R1CNR2CNR1ATM | |
| SCHEMBL20688434 | 0.88 | CHRNB4 (0.33) | ATMCHRNB4CHRNA3 | |
| SCHEMBL20696888 | 0.88 | CHRNB4 (0.33) | ATMCHRNB4CHRNA3 | |
| SCHEMBL20688098 | 0.88 | CHRNB4 (0.33) | ATMCHRNB4CHRNA3 | |
| SCHEMBL20696902 | 0.88 | CHRNB4 (0.33) | ATMCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-11220506-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors | BEIGENE, LTD. (KY) | 2022-01-11 | — | — | US | disclosed |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | FIREMENICH INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-106107406-B | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers | 弗门尼舍公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
| EP-2552207-B1 | SWEET FLAVOR MODIFIER | FIRMENICH INCORPORATED (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED | 2019-07-11 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | SENOMYX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20140128481-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8592592-B2 | Sweet flavor modifier | SENOMYX, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2603098-A2 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | Senomyx, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| CN-103153096-A | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers | SENOMYX INC | 2013-06-12 | — | — | CN | disclosed |
| CN-102933081-A | Sweet flavor modifier | SENOMYX INC | 2013-02-13 | — | — | CN | disclosed |
| EP-2552207-A1 | SWEET FLAVOR MODIFIER | Senomyx, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120041078-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012021837-A2 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011123693-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245353-A1 | SWEET FLAVOR MODIFIER | SENOMYS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | TAS1R3 2900/4885TAS1R1 3273/4885CNR2 2177/4885 |
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | TAS1R3 406/4885TAS1R1 289/4885CNR2 3043/4885 |
| US-20120041078-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | TAS1R3 406/4885TAS1R1 289/4885CNR2 3043/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | TAS1R3 2900/4885TAS1R1 3273/4885CNR2 2177/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | TAS1R3 2900/4885TAS1R1 3273/4885CNR2 2177/4885 |
| US-20110245353-A1 | SWEET FLAVOR MODIFIER | TAS2R5, TAS2R10, TAS2R50 | TAS1R3 18/4885TAS1R1 13/4885CNR2 2402/4885 |
| US-20140128481-A1 | SWEET FLAVOR MODIFIER | TAS2R5, TAS2R10, TAS2R50 | TAS1R3 18/4885TAS1R1 13/4885CNR2 2402/4885 |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | TAS1R3 406/4885TAS1R1 289/4885CNR2 3043/4885 |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | TAS1R3 406/4885TAS1R1 289/4885CNR2 3043/4885 |
| US-11220506-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors | PIK3CD, PIK3R5, PIK3CA | TAS1R3 2477/4885TAS1R1 2057/4885CNR2 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.